• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

亨廷顿病：已知正电子发射断层扫描成像生物标志物和靶向放射性示踪剂的综述。

Huntington's Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers.

机构信息

Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Geert Grooteplein-Zuid 10, 6525 EZ Nijmegen, The Netherlands.

Radboud Translational Medicine B.V., Radboud University Medical Center, Geert Grooteplein 21 (route 142), 6525 EZ Nijmegen, The Netherlands.

出版信息

Molecules. 2020 Jan 23;25(3):482. doi: 10.3390/molecules25030482.

DOI:10.3390/molecules25030482
PMID:31979301
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7038198/
Abstract

Huntington's disease (HD) is a fatal neurodegenerative disease caused by a CAG expansion mutation in the gene. As a result, intranuclear inclusions of mutant huntingtin protein are formed, which damage striatal medium spiny neurons (MSNs). A review of Positron Emission Tomography (PET) studies relating to HD was performed, including clinical and preclinical data. PET is a powerful tool for visualisation of the HD pathology by non-invasive imaging of specific radiopharmaceuticals, which provide a detailed molecular snapshot of complex mechanistic pathways within the brain. Nowadays, radiochemists are equipped with an impressive arsenal of radioligands to accurately recognise particular receptors of interest. These include key biomarkers of HD: adenosine, cannabinoid, dopaminergic and glutamateric receptors, microglial activation, phosphodiesterase 10 A and synaptic vesicle proteins. This review aims to provide a radiochemical picture of the recent developments in the field of HD PET, with significant attention devoted to radiosynthetic routes towards the tracers relevant to this disease.

摘要

亨廷顿病（HD）是一种致命的神经退行性疾病，由基因中的 CAG 扩展突变引起。结果，形成了突变亨廷顿蛋白的核内包涵体，从而破坏纹状体中型棘突神经元（MSNs）。对与 HD 相关的正电子发射断层扫描（PET）研究进行了综述，包括临床前和临床数据。PET 是一种通过非侵入性成像特定放射性药物来可视化 HD 病理学的强大工具，它提供了大脑内复杂机制途径的详细分子快照。如今，放射化学家拥有令人印象深刻的放射性配体武器库，可准确识别感兴趣的特定受体。这些包括 HD 的关键生物标志物：腺苷、大麻素、多巴胺能和谷氨酸能受体、小胶质细胞激活、磷酸二酯酶 10A 和突触囊泡蛋白。本综述旨在提供 HD PET 领域的最新发展的放射化学图景，重点关注与该疾病相关示踪剂的放射合成途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/d67c97ebba48/molecules-25-00482-sch014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/8a1f53af2409/molecules-25-00482-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/b1a5b05f3e1d/molecules-25-00482-sch002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/1c88bd495bf8/molecules-25-00482-sch003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/d2dcca630f86/molecules-25-00482-sch004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/5e12cb4fabd4/molecules-25-00482-sch005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/751caed204be/molecules-25-00482-sch006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/3940cf9b9cad/molecules-25-00482-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/df5b2ed69967/molecules-25-00482-sch007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/506980ba3224/molecules-25-00482-sch008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/22033460bb75/molecules-25-00482-sch009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/4b77e88457ab/molecules-25-00482-sch010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/943a75471554/molecules-25-00482-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/c3c79e36c770/molecules-25-00482-sch011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/7033c21210a5/molecules-25-00482-sch012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/25212a518ab0/molecules-25-00482-sch013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/b4992e56f070/molecules-25-00482-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/d67c97ebba48/molecules-25-00482-sch014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/8a1f53af2409/molecules-25-00482-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/b1a5b05f3e1d/molecules-25-00482-sch002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/1c88bd495bf8/molecules-25-00482-sch003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/d2dcca630f86/molecules-25-00482-sch004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/5e12cb4fabd4/molecules-25-00482-sch005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/751caed204be/molecules-25-00482-sch006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/3940cf9b9cad/molecules-25-00482-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/df5b2ed69967/molecules-25-00482-sch007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/506980ba3224/molecules-25-00482-sch008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/22033460bb75/molecules-25-00482-sch009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/4b77e88457ab/molecules-25-00482-sch010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/943a75471554/molecules-25-00482-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/c3c79e36c770/molecules-25-00482-sch011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/7033c21210a5/molecules-25-00482-sch012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/25212a518ab0/molecules-25-00482-sch013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/b4992e56f070/molecules-25-00482-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8aad/7038198/d67c97ebba48/molecules-25-00482-sch014.jpg

相似文献

1
Huntington's Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers.亨廷顿病：已知正电子发射断层扫描成像生物标志物和靶向放射性示踪剂的综述。
Molecules. 2020 Jan 23;25(3):482. doi: 10.3390/molecules25030482.
2
Molecular Imaging in Huntington's Disease.亨廷顿病的分子影像学。
Int Rev Neurobiol. 2018;142:289-333. doi: 10.1016/bs.irn.2018.08.007. Epub 2018 Aug 29.
3
The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease.磷酸二酯酶 10 正电子发射断层扫描示踪剂 [18F]MNI-659 作为早期亨廷顿病的新型生物标志物。
JAMA Neurol. 2014 Dec;71(12):1520-8. doi: 10.1001/jamaneurol.2014.1954.
4
PET Imaging in Huntington's Disease.亨廷顿舞蹈病的正电子发射断层显像（PET）成像
J Huntingtons Dis. 2015;4(4):287-96. doi: 10.3233/JHD-150171.
5
Molecular Imaging Markers to Track Huntington's Disease Pathology.用于追踪亨廷顿舞蹈病病理的分子成像标记物
Front Neurol. 2017 Jan 30;8:11. doi: 10.3389/fneur.2017.00011. eCollection 2017.
6
Current status of PET imaging in Huntington's disease.正电子发射断层显像（PET）在亨廷顿舞蹈症中的应用现状
Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1171-82. doi: 10.1007/s00259-016-3324-6. Epub 2016 Feb 22.
7
PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease.正电子发射断层扫描（PET）对亨廷顿舞蹈病神经退行性变过程中突触前和突触后多巴胺能标志物的研究。
Brain. 1997 Mar;120 ( Pt 3):503-14. doi: 10.1093/brain/120.3.503.
8
Microglial activation in presymptomatic Huntington's disease gene carriers.症状前亨廷顿舞蹈病基因携带者的小胶质细胞激活
Brain. 2007 Jul;130(Pt 7):1759-66. doi: 10.1093/brain/awm044. Epub 2007 Mar 30.
9
Imaging microglial activation in Huntington's disease.亨廷顿舞蹈病中成像小胶质细胞激活
Brain Res Bull. 2007 Apr 30;72(2-3):148-51. doi: 10.1016/j.brainresbull.2006.10.029. Epub 2006 Nov 27.
10
Radioligands for the dopamine receptor subtypes.多巴胺受体亚型的放射性配体。
J Labelled Comp Radiopharm. 2013 Mar-Apr;56(3-4):130-48. doi: 10.1002/jlcr.3000.

引用本文的文献

1
Neuroimaging Techniques in Huntington's Disease: A Critical Review.亨廷顿病的神经影像学技术：批判性综述
Mov Disord Clin Pract. 2025 May;12(5):561-576. doi: 10.1002/mdc3.70010. Epub 2025 Feb 20.
2
Neuroimaging to Facilitate Clinical Trials in Huntington's Disease: Current Opinion from the EHDN Imaging Working Group.神经影像学在亨廷顿病临床试验中的应用：EHDN 影像学工作组的最新观点。
J Huntingtons Dis. 2024;13(2):163-199. doi: 10.3233/JHD-240016.
3
The contribution of preclinical magnetic resonance imaging and spectroscopy to Huntington's disease.

本文引用的文献

1
Positron Emission Tomography in Pediatric Neurodegenerative Disorders.正电子发射断层扫描在儿科神经退行性疾病中的应用。
Pediatr Neurol. 2019 Nov;100:12-25. doi: 10.1016/j.pediatrneurol.2019.07.003. Epub 2019 Jul 17.
2
CAG Repeat Not Polyglutamine Length Determines Timing of Huntington's Disease Onset.CAG 重复序列而非多聚谷氨酰胺长度决定亨廷顿病发病时间。
Cell. 2019 Aug 8;178(4):887-900.e14. doi: 10.1016/j.cell.2019.06.036.
3
Validation and noninvasive kinetic modeling of [C]UCB-J PET imaging in mice.在小鼠中进行 [C]UCB-J PET 成像的验证和无创动力学建模。
临床前磁共振成像和光谱学对亨廷顿舞蹈病的贡献。
Front Aging Neurosci. 2024 Feb 13;16:1306312. doi: 10.3389/fnagi.2024.1306312. eCollection 2024.
4
From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington's Disease Research.从发病机制到治疗：亨廷顿病研究 150 年回顾。
Int J Mol Sci. 2023 Aug 21;24(16):13021. doi: 10.3390/ijms241613021.
5
Raclopride-Molecularly Imprinted Polymers: A Promising Technology for Selective [C]Raclopride Purification.雷氯必利-分子印迹聚合物：一种用于选择性纯化[C]雷氯必利的有前景的技术。
Materials (Basel). 2023 Jan 27;16(3):1091. doi: 10.3390/ma16031091.
6
Multimodality imaging of neurodegenerative disorders with a focus on multiparametric magnetic resonance and molecular imaging.神经退行性疾病的多模态成像，重点关注多参数磁共振成像和分子成像。
Insights Imaging. 2023 Jan 16;14(1):8. doi: 10.1186/s13244-022-01358-6.
7
Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.正电子发射断层扫描和单光子发射计算机断层扫描用放射性药物：过去十年的文献综述。
Int J Mol Sci. 2022 Apr 30;23(9):5023. doi: 10.3390/ijms23095023.
8
Synthesis and Evaluation of a Fluorine-18 Radioligand for Imaging Huntingtin Aggregates by Positron Emission Tomographic Imaging.用于正电子发射断层成像的18F放射性配体的合成与评价，用于亨廷顿蛋白聚集体成像
Front Neurosci. 2021 Dec 2;15:766176. doi: 10.3389/fnins.2021.766176. eCollection 2021.
9
Novel Tracers and Radionuclides in PET Imaging.正电子发射断层扫描中的新型示踪剂和放射性核素
Radiol Clin North Am. 2021 Sep;59(5):887-918. doi: 10.1016/j.rcl.2021.05.012.
10
Purinergic Signaling in the Pathophysiology and Treatment of Huntington's Disease.嘌呤能信号在亨廷顿舞蹈病病理生理学及治疗中的作用
Front Neurosci. 2021 Jul 1;15:657338. doi: 10.3389/fnins.2021.657338. eCollection 2021.
J Cereb Blood Flow Metab. 2020 Jun;40(6):1351-1362. doi: 10.1177/0271678X19864081. Epub 2019 Jul 15.
4
Synaptic vesicle protein 2A as a potential biomarker in synaptopathies.突触囊泡蛋白 2A 作为突触病的潜在生物标志物。
Mol Cell Neurosci. 2019 Jun;97:34-42. doi: 10.1016/j.mcn.2019.02.001. Epub 2019 Feb 20.
5
Insights into GABAergic system alteration in Huntington's disease.对亨廷顿病中 GABA 能系统改变的深入了解。
Open Biol. 2018 Dec 5;8(12):180165. doi: 10.1098/rsob.180165.
6
Targeting the proteostasis network in Huntington's disease.靶向亨廷顿病的蛋白稳态网络。
Ageing Res Rev. 2019 Jan;49:92-103. doi: 10.1016/j.arr.2018.11.006. Epub 2018 Nov 28.
7
Novel Imaging Biomarkers for Huntington's Disease and Other Hereditary Choreas.新型亨廷顿病和其他遗传性舞蹈病的成像生物标志物。
Curr Neurol Neurosci Rep. 2018 Oct 5;18(12):85. doi: 10.1007/s11910-018-0890-y.
8
Microglia in neurodegeneration.神经退行性疾病中的小胶质细胞。
Nat Neurosci. 2018 Oct;21(10):1359-1369. doi: 10.1038/s41593-018-0242-x. Epub 2018 Sep 26.
9
PET Radioligands for imaging of the PDE10A in human: current status.用于人体磷酸二酯酶10A成像的正电子发射断层显像放射性配体：现状
Neurosci Lett. 2019 Jan 19;691:11-17. doi: 10.1016/j.neulet.2018.08.006. Epub 2018 Aug 10.
10
[C]SCH23390 binding to the D-dopamine receptor in the human brain-a comparison of manual and automated methods for image analysis.[C]SCH23390与人脑D-多巴胺受体的结合——图像分析的手动与自动方法比较
EJNMMI Res. 2018 Aug 2;8(1):74. doi: 10.1186/s13550-018-0416-2.